Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole vs Ranitidine for Hemostasis Maintenance in Peptic Ulcer
NCT00247130Phase 4
Key facts
- Status
- Withdrawn
- Start
- Oct 2005
- Primary completion
- Jul 2007
- Countries
- 1
- Sponsor
- Keio University
- Modality
- Small Molecules
- Drugs
- omeprazole
- Conditions
- peptic ulcer disease (PUD)
01
Overview
Phase 4, randomised trial of omeprazole in peptic ulcer disease (PUD), sponsored by Keio University. Primary endpoint: No evidence of hemorrhage or vessel exposure on a second endoscopy at 4 weeks. Planned start Oct 2005; status: withdrawn.
02
Design
- Study design
- Randomized
03
Who it enrols
Patients over 20 with gastric or duodenal ulcers requiring endoscopic hemostasis for active bleeding or exposed vessels, excluding those with major organ failure, malignancy, or drug allergies.
04
Endpoints
Primary
No evidence of hemorrhage or vessel exposure on a second endoscopy
Secondary
Plasma ghrelin levels
Beyond the preview
Go deeper on NCT00247130.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247130.